Decreased Diversity of the Fecal Microbiome in Recurrent Clostridium difficile–Associated Diarrhea
The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
Antibiotic-associated diarrhea due to Clostridium difficile (CDAD) is thought to reflect colonization of a disrupted microbial community by the pathogen. We profiled the fecal microbiota of patients with CDAD (both initial and recurrent episodes) by culture-independent phylogenetic analysis of 16S rRNA-encoding gene sequences. Compared with those from control subjects and patients with an initial episode, the fecal communities in patients with recurrent CDAD were highly variable in bacterial composition and were characterized by markedly decreased diversity. Preservation and restoration of the microbial diversity could represent novel strategies for prevention and treatment of recurrent CDAD, which is often recalcitrant to existing therapies.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Conversely, a small, open label pilot study comparing upper and lower GI routes of administration did not show any differences44”
From Update on Fecal Microbiota Transplantation 2015: Indications, Methodologies, Mechanisms, and Outlook (2015) · cites this paper as [44]
In the citing paper
“The human gut microbiota can restrict the growth of pathogens to prevent them from colonizing the intestine (‘colonization resistance’).”
From Role of the gut microbiota in nutrient competition and protection against intestinal pathogen colonization (2023) · cites this paper as [28]
In the citing paper
“Gut microbiota with high diversity have higher colonization resistance than gut microbiota with low diversity as a result of antibiotic treatment [28].”
From Role of the gut microbiota in nutrient competition and protection against intestinal pathogen colonization (2023) · cites this paper as [28]
Citations
Cites
Measuring biological diversity
(2004) · Choice Reviews Online · doi:10.5860/choice.42-1547 · Cited by 6,621
Ecological and Evolutionary Forces Shaping Microbial Diversity in the Human Intestine
Ley, R. E., Peterson, D. A., & Gordon, J. I. (2006) · Cell · doi:10.1016/j.cell.2006.02.017 · Cited by 3,358 · cited 3×
“exist in a complex symbiosis with their host [5].”
BackgroundInfluentialSchloss, P. D., & Handelsman, J. (2005) · Applied and Environmental Microbiology · doi:10.1128/aem.71.3.1501-1506.2005 · Cited by 2,501 · cited 1×
“The distance matrix was fed into DOTUR [8] to group the sequences into operational taxonomic units (OTUs), calculate ecological diversity measures (including the Shannon index [9]), and generate rarefaction curves by use of an OTU definition of 97% sequence similarity.”
MethodAntibiotic-Associated Diarrhea
Bartlett, J. G. (2002) · New England Journal of Medicine · doi:10.1056/nejmcp011603 · Cited by 1,197 · cited 1×
“Diarrhea is a common side effect of the administration of antibiotics, with Clostridium difficile being responsible for most of the severe cases of antibiotic-associated diarrhea (AAD), including the development of pseudomembranous colitis [1].”
BackgroundMcFarland, L. V. (2006) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2006.00465.x · Cited by 872 · cited 1×
“difficile antibiotics or the administration of probiotic organisms— have been tried for treatment of RCD [12, 13] [14].”
BackgroundKyne, L., Warny, M., Qamar, A., & Kelly, C. P. (2001) · The Lancet · doi:10.1016/s0140-6736(00)03592-3 · Cited by 804 · cited 1×
“difficile toxin [11].”
Breaking The Cycle: Treatment Strategies for 163 Cases of Recurrent Clostridium Difficile Disease
McFarland, L. V., Elmer, G. W., & Surawicz, C. M. (2002) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2002.05839.x · Cited by 724 · cited 1×
“difficile antibiotics or the administration of probiotic organisms— have been tried for treatment of RCD [12, 13] [14].”
BackgroundAas, J., Gessert, C. E., & Bakken, J. S. (2003) · Clinical Infectious Diseases · doi:10.1086/367657 · Cited by 518 · cited 1×
“individuals to patients with RCD [4, 15]—is to alter the patient’s microbiome and to restore colonization resistance.”
BackgroundBACTERIOTHERAPY FOR CHRONIC RELAPSING CLOSTRIDIUM DIFFICILE DIARRHOEA IN SIX PATIENTS
Tvede, M., & Rask-Madsen, J. (1989) · The Lancet · doi:10.1016/s0140-6736(89)92749-9 · Cited by 491
Vollaard, E. J., & Clasener, H. A. (1994) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.38.3.409 · Cited by 478 · cited 1×
“microbiota is that of “colonization resistance” [10].”
Cited by
Items 601–700 of 999
Gotoh, K., Sakaguchi, Y. M., Kato, H., Osaki, H., Jodai, Y., Wakuda, M., Take, A., Hayashi, S., Morita, E., 杉江, 岳., et al. (2021) · Anaerobe · doi:10.1016/j.anaerobe.2021.102502 · Cited by 17
Beyi, A. F., Wannemuehler, M. J., & Plummer, P. J. (2022) · Antibiotics · doi:10.3390/antibiotics11081093 · Cited by 19
Stroke, I. L., Letourneau, J. J., Miller, T. E., Xu, Y., Pechik, I. V., Savoly, D. R., Ma, L., Sturzenbecker, L. J., Sabalski, J. E., Stein, P. D., et al. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00107-18 · Cited by 16
“therapy used to treat CDI (5) and (ii) a failure by the patient to produce neutralizing antitoxin antibodies that protect against disease (6, 7).”
BackgroundThe Unknown Effect of Antibiotic-Induced Dysbiosis on the Gut Microbiota
Birg, A., Ritz, N. L., & Lin, H. C. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-815249-2.00020-8 · Cited by 19
Gupta, A. K., Wash, C., Wu, Y., Sorrentino, D. R., & Nguyen, V. Q. C. (2020) · Digestive Diseases and Sciences · doi:10.1007/s10620-020-06205-6 · Cited by 19
Clostridioides difficile carriage in animals and the associated changes in the host fecal microbiota
Thanissery, R., McLaren, M. R., Rivera, A. J., Reed, A. D., Betrapally, N. S., Burdette, T., Winston, J. A., Jacob, M. E., Callahan, B. J., & Theriot, C. M. (2020) · Anaerobe · doi:10.1016/j.anaerobe.2020.102279 · Cited by 23
Origins of scaling laws in microbial dynamics
Wang, X., & Liu, Y. (2023) · Physical Review Research · doi:10.1103/physrevresearch.5.013004 · Cited by 18
Larsen, I., Chenaux, M., Collins, F. W. J., Mandić, A. D., Hansen, L. B. S., Lauridsen, C., Haller, R. F., Elvig-Jørgensen, S. G., Horwell, E., Christiansen, J., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-42128-8 · Cited by 15
Advancements in Novel Live Biotherapeutic Products for Clostridioides difficile Infection Prevention
Lavoie, T., Appaneal, H. J., & LaPlante, K. L. (2023) · Clinical Infectious Diseases · doi:10.1093/cid/ciad639 · Cited by 17
Harpe, S. E., Inocencio, T. J., Pakyz, A. L., Oinonen, M. J., & Polk, R. E. (2012) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/j.1875-9114.2012.01160.x · Cited by 14
“Therefore, we stratified patients according to receipt of one, two, three, or four or more antibacterials administered not more than 7 days before the diagnosis of CDI.”
ResultInfluentialClostridium difficile: improving the prevention paradigm in healthcare settings
Vassallo, A., Tran, M.-C. N., & Goldstein, E. J. C. (2014) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.2014.942284 · Cited by 17
“The components of firmicutes and other types of bacteria have been noted to be altered in patients who develop CDI, and those who have relapses of CDI when compared with control populations [23].”
BackgroundLees, E. A., Carrol, E. D., Ellaby, N. A. F., Roberts, P., Corless, C. E., Lenzi, L., Darby, A. C., O’Brien, S. J., Cunliffe, N. A., Turner, M. A., et al. (2019) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0000000000002559 · Cited by 15
Voided Urinary Microbiota Is Stable Over Time but Impacted by Post Void Storage
Bundgaard‐Nielsen, C., Ammitzbøll, N., Isse, Y. A., Muqtar, A., Jensen, A.-M., Leutscher, P. D. C., Arenholt, L. T. S., Hagstrøm, S., & Sørensen, S. (2020) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2020.00435 · Cited by 17
“However, when brought out of balance (dysbiosis), the same microorganisms have been associated with several pathological states including infections (Chang et al., 2008),”
BackgroundFecal Microbiota Transplantation and Emerging Treatments for Clostridium difficile Infection
Gens, K. D., Elshaboury, R. H., & Holt, J. (2013) · Journal of Pharmacy Practice · doi:10.1177/0897190013499527 · Cited by 17
“Compared with those from control subjects and patients with an initial CDI episode, the fecal communities in patients with recurrent CDI were highly variable in bacterial composition and were characterized by markedly decreased diversity.(17) In another study, fecal samples from 9 infants who received parenteral ampic…”
BackgroundResultThe Human Microbiome and Infectious Diseases: Beyond Koch
Young, V. B., Britton, R. A., & Schmidt, T. M. (2008) · Interdisciplinary Perspectives on Infectious Diseases · doi:10.1155/2008/296873 · Cited by 17
Self-citationProgress in Our Understanding of the Gut Microbiome: Implications for the Clinician
Iqbal, S., & Quigley, E. M. M. (2016) · Current Gastroenterology Reports · doi:10.1007/s11894-016-0524-y · Cited by 20
Seekatz, A. M., Bassis, C. M., Fogg, L., Moore, N. M., Rhee, Y., Lolans, K., Weinstein, R. A., Lin, M. Y., Young, V. B., & Hayden, M. K. (2018) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofy190 · Cited by 15
“difficile infection, which is a rationale for treating this infection with microbiota transplantation [35, 36].”
BackgroundSelf-citationCheng, Y., & Fischer, M. (2020) · Clinics in Colon and Rectal Surgery · doi:10.1055/s-0040-1701233 · Cited by 18
FMT: First Step in a Long Journey
Brandt, L. J. (2013) · The American Journal of Gastroenterology · doi:10.1038/ajg.2013.165 · Cited by 17
Sulfated dietary fiber protects gut microbiota from antibiotics
Wu, F., Yu, X. A., Angeles-Albores, D., Erdman, S. E., & Alm, E. J. (2025) · Microbiome · doi:10.1186/s40168-025-02176-w · Cited by 18
Chang, J., Jia, X., Liu, Y., Jiang, X., Che, L., Lin, Y., Zhuo, Y., Feng, B., Fang, Z., Li, J., et al. (2024) · Animals · doi:10.3390/ani14010162 · Cited by 16
Self-citationThe immune interactions of gut glycans and microbiota in health and disease
(2024) · doi:10.1111/mmi.15267 · Cited by 14
Kump, P. K., & Högenauer, C. (2016) · Digestive Diseases · doi:10.1159/000447379 · Cited by 14
Villafuerte-Gálvez, J., & Kelly, C. P. (2017) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2017.1344551 · Cited by 14
“A study examining the gut microbiota showed that patients with rCDI have a highly altered bacterial composition as well as significantly lower bacterial diversity indices when compared to healthy controls or to patients with primary CDI [23].”
BackgroundEuropean Practice for CDI Treatment
Fitzpatrick, F., Skally, M., Brady, M., Burns, K., Rooney, C. M., & Wilcox, M. H. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-72799-8_8 · Cited by 19
Baumgartner, M., Pfrunder‐Cardozo, K. R., & Hall, A. R. (2021) · Proceedings of the Royal Society B Biological Sciences · doi:10.1098/rspb.2020.3106 · Cited by 17
“Summary metrics, such as 370 species diversity as we analyzed above, may help here, and have been correlated with some 371 microbiota-related properties such as risk of obesity [37], diabetes [38] and recurrent infection 372 with Clostridium difficile [39].”
BackgroundRadisavljevic, N., Cirstea, M. S., Bauer, K. C., Lo, C., Metcalfe‐Roach, A., Bozorgmehr, T., Bar‐Yoseph, H., & Finlay, B. B. (2022) · Journal of Parkinson s Disease · doi:10.3233/jpd-223165 · Cited by 17
Xu, Q., Zhang, S., Quan, J., Wu, Z., Gu, S., Chen, Y., Zheng, B., Lv, L., & Li, L. (2022) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-022-12154-z · Cited by 14
The Microbiome in Infectious Diseases
Mitreva, M. (2016) · Elsevier eBooks · doi:10.1016/b978-0-7020-6285-8.00008-3 · Cited by 20
Kim, M.-H., Kuehn, L. A., Bono, J. L., Berry, E. D., Kalchayanand, N., Freetly, H. C., Benson, A. K., & Wells, J. E. (2017) · Journal of Applied Microbiology · doi:10.1111/jam.13545 · Cited by 17
“difficile were found to harbour a less diverse faecal microbiota that was highly variable between patients, than did normal patients (Chang et al. 2008).”
BackgroundThe Current Hepatic Encephalopathy Pipeline
Ryu, A. J., Rahimi, R. S., & Leise, M. D. (2020) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2020.01.001 · Cited by 15
Evolution of clinical guidelines for antimicrobial management of Clostridioides difficile infection
Chaar, A., & Feuerstadt, P. (2021) · Therapeutic Advances in Gastroenterology · doi:10.1177/17562848211011953 · Cited by 14
Within-host competition causes pathogen molecular evolution and perpetual microbiota dysbiosis
Stevens, E. J., Li, J., Hector, T. E., Drew, G., Hoang, K. L., Greenrod, S. T. E., Paterson, S., & King, K. C. (2025) · The ISME Journal · doi:10.1093/ismejo/wraf071 · Cited by 16
“Here, upon initial invasion of nematode hosts, S. aureus displaced resident microbiota (in terms of number and diversity) worsening disease outcome, comparable to results observed with other bacterial pathogens [58].”
Clostridioides difficile Infection: Landscape and Microbiome Therapeutics.
Gawey, B. J., & Khanna, S. (2023) · PubMed Central · Cited by 17
The Gut Microbiome: A Primer for the Clinician
Aroniadis, O. C., & Grinspan, A. M. (2023) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000002583 · Cited by 18
“The body of literature supporting the use ofLBP for the treatment and prevention of recurrent CDI is growing and will be described in subsequent sections of this monograph.”
BackgroundInfluentialTreatment of Clostridium difficile Infections
Soriano, M. M., & Johnson, S. (2015) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2014.11.005 · Cited by 13
“Recent data using nonculture techniques to elaborate the diversity and abundance of the fecal microbiome show a progressive loss of diversity and drop out of major bacterial groups starting with healthy patients compared with patients with initial CDI episodes, and then compared with patients with recurrent CDI.79 Wit…”
ResultInfluentialBono‐Lunn, D., Villeneuve, C., Abdulhay, N. J., Harker, M. J., & Parker, W. (2016) · Clinical Research and Regulatory Affairs · doi:10.1080/10601333.2016.1210159 · Cited by 12
“Loss of beneficial bacteria from the gut Broad spectrum antibiotics Clostridium difficile associated colitis (70,71) Formation of agency with authority and resources to pursue FMTs until they are standard of care for recurrent C.”
BackgroundLaffin, M., Perry, T., Park, H., Hotte, N., Fedorak, R., Thiesen, A., Dicken, B., & Madsen, K. (2017) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izx033 · Cited by 11
Zhao, N., Luo, Y., Bian, Q., Wang, L., Ye, J., Song, X., Jiang, J., Tang, Y., Wang, X., & Jin, D. (2020) · Infection and Drug Resistance · doi:10.2147/idr.s238916 · Cited by 13
Wang, H., Yue, X., Yu, J., Wang, R. Y., Teng, S., Fang, J., & Liu, B. (2020) · Journal of Oceanology and Limnology · doi:10.1007/s00343-020-9217-3 · Cited by 13
Dembrovszky, F., Gede, N., Szakács, Z., Hegyi, P. J., Kiss, S., Farkas, N., Molnár, Z., Imrei, M., Dohos, D., & Péterfi, Z. (2020) · Infectious Diseases and Therapy · doi:10.1007/s40121-020-00356-9 · Cited by 14
Chanyi, R. M., Craven, L. J., Harvey, B., Reid, G., Silverman, M., & Burton, J. P. (2017) · SAGE Open Medicine · doi:10.1177/2050312117708712 · Cited by 15
Horvat, S., Mahnič, A., Breskvar, M., Džeroski, S., & Rupnik, M. (2017) · Scientific Reports · doi:10.1038/s41598-017-15434-1 · Cited by 16
Liu, H., Wu, H., & Wang, Q. (2018) · International Journal of Food Science & Technology · doi:10.1111/ijfs.14050 · Cited by 14
Herrera, G., Paredes‐Sabja, D., Patarroyo, M. A., Ramírez, J. D., & Muñoz, M. (2021) · Gut Microbes · doi:10.1080/19490976.2021.1966277 · Cited by 13
Carr, A. V., Baliga, N. S., Diener, C., & Gibbons, S. M. (2023) · Cell Systems · doi:10.52843/cassyni.23jzlp · Cited by 31
Therapy for Clostridium difficile infection – any news beyond Metronidazole and Vancomycin?
Manthey, C. F., Eckmann, L., & Fuhrmann, V. (2017) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2017.1362978 · Cited by 16
Ramsay, I. D., Brown, N. M., & Enoch, D. (2018) · Infectious Diseases Research and Treatment · doi:10.1177/1178633718758023 · Cited by 14
Metabolic Modeling of Clostridium difficile Associated Dysbiosis of the Gut Microbiota
Phalak, P., & Henson, M. A. (2019) · Processes · doi:10.3390/pr7020097 · Cited by 12
“difficile infection (CDI) is most common in patients previously treated with broad spectrum antibiotics that disrupt the healthy gut microbiota and reduce competition for available nutrients [29], resulting in dysbiosis conducive to C.”
BackgroundPrevention and treatment of recurrent Clostridioides difficile infection
Shin, J. H., & Warren, C. A. (2019) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000587 · Cited by 12
STRUCTURING A FECAL MICROBIOTA TRANSPLANTATION CENTER IN A UNIVERSITY HOSPITAL IN BRAZIL
Terra, D., Vilela, E. G., Silva, R. O. S., LEÃO, L. A., Karine Sampaio, L. I. M. A., PASSOS, R. I. F. Â., Diniz, A. N., & Coelho, L. G. V. (2020) · Arquivos de Gastroenterologia · doi:10.1590/s0004-2803.202000000-79 · Cited by 11
“Nonetheless, after recurrent episodes of CDI, there is a marked reduction in Bacteroidetes accompanied by a marked increase in other phylums that are usually a minority in intestinal microbiota(147).”
BackgroundChopra, T. (2023) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2023.2171986 · Cited by 15
Fecal microbiota transplantation stimulates type 2 and tolerogenic immune responses in a mouse model
Moreau, G. B., Naz, F., & Petri, W. A. (2024) · Anaerobe · doi:10.1016/j.anaerobe.2024.102841 · Cited by 12
Controversies Around Epidemiology, Diagnosis and Treatment of Clostridium difficile Infection
Marra, F., & Ng, K. (2015) · Drugs · doi:10.1007/s40265-015-0422-x · Cited by 20
Fecal Microbiota Therapy With a Focus on Clostridium difficile Infection
Brandt, L. J. (2017) · Psychosomatic Medicine · doi:10.1097/psy.0000000000000511 · Cited by 14
“patients with R-CDI have been shown to lack the phylogenetic diversity and richness that typify the stool of normal individuals and, to a lesser degree, the stool of patients who have had only one bout of CDI (24).”
BackgroundRamos, A., Martínez-Ruiz, R., Múñez, E., Alijo, Á. V., Ferre‐Aracil, C., & Vera-Mendoza, M. I. (2020) · Journal of Hospital Infection · doi:10.1016/j.jhin.2020.01.016 · Cited by 12
Chen, L. A., Hourigan, S. K., Grigoryan, Z., Gao, Z., Clemente, J. C., Rideout, J. R., Chirumamilla, S. R., Rabidazeh, S., Saeed, S. A., Elson, C. O., et al. (2018) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0000000000002210 · Cited by 16
Optimum health and inhibition of cancer progression by microbiome and resveratrol
Stokes, J. A., III, Vinayak, S., Williams, J., Malik, S., Singh, R., Manne, U., Owonikoko, T. K., & Mishra, M. K. (2021) · Frontiers in bioscience · doi:10.2741/4904 · Cited by 11
“Dysbiosis is exemplified in inflammatory bowel disease (IBD), for which the bacterial composition typically shifts to a community that contains fewer Bacteroidetes and Firmicutes, and more from the phylas Actinobacteria and Proteobacteria (36).”
BackgroundLarrainzar-Coghen, T., Rodríguez-Pardo, D., Barba, P., Rodríguez, V., Roig, G., Ferrer, C., Ruíz-Camps, I., & Almirante, B. (2018) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-018-3341-4 · Cited by 12
Chauhan, U., Popov, J., Farbod, Y., Kalantar, M., Wolfe, M., Moayyedi, P., Marshall, J. K., Halder, S. L. S., & Kaasalainen, S. (2021) · Journal of the Canadian Association of Gastroenterology · doi:10.1093/jcag/gwab007 · Cited by 14
“FMT has gained acceptance as standard therapy for the treatment of RCDI with proven efficacy, safety and patient tolerability (7,8).”
BackgroundInfluentialIs Regular Probiotic Practice Safe for Management of Sepsis?
Kumar, R., Tripathi, A. S., Sharma, N., Singh, G., & Mohapatra, L. (2021) · Chinese Journal of Integrative Medicine · doi:10.1007/s11655-021-3334-5 · Cited by 12
Clostridium difficile Infection
Feuerstadt, P. (2015) · Clinical and Translational Gastroenterology · doi:10.1038/ctg.2015.13 · Cited by 12
“This study showed that patients with recurrent CDI have less diverse bacterial colonization with a deficiency of bacteroidetes and firmicutes.(16) A recent group of studies published as a single manuscript used a murine model of CDI combined with a human cohort to clarify microbiome changes with various antimicrobial’…”
Frank, D. N. (2010) · Journal of Animal Science · doi:10.2527/jas.2010-3392 · Cited by 13
Treatment of Refractory or RecurrentClostridium difficileInfection
Kim, S. W. (2012) · Korean Journal of Gastroenterology · doi:10.4166/kjg.2012.60.2.71 · Cited by 13
“정상인과 CDI 환자의 장내 균총을 비교하여 보면 정상인과 처음 CDI를 진단받은 환자는 Bacteroidetes와 Firmicutes가 주된 균총인데 반해 재발성 CDI 환자에서는 장 균총이 전반적으로 감소되어 있고 정상과 는 달리 Bacteroidetes와 Firmicutes가 주된 균총이 아니었 다.(32) 이식된 대변은 또 대장의 항상성을 유지하는 세균 생산 물인 단쇄지방산(short chain fatty acid)을 회복시키고 정상 화하는 역할을 한다.”
The Contribution of Strains and Hosts to Outcomes in Clostridium difficile Infection
Martin, J. S. H. (2015) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2014.11.012 · Cited by 13
The Intestinal Microbiota and Human Disease
Ko, J. S. (2013) · Korean Journal of Gastroenterology · doi:10.4166/kjg.2013.62.2.85 · Cited by 13
“difficile 감염을 경험한 사람에 비해 서 다양성이 현저히 감소한다.(60) 반복적인 C.”
The Human Microbiome of Local Body Sites and Their Unique Biology
Aagaard, K. M., Luna, R. A., & Versalovic, J. A. (2015) · Elsevier eBooks · doi:10.1016/b978-1-4557-4801-3.00002-3 · Cited by 16
Oral Vancomycin for Secondary Prophylaxis of Clostridium difficile Infection
Brown, C. C., Manis, M. M., Bohm, N. M., & Curry, S. R. (2018) · Annals of Pharmacotherapy · doi:10.1177/1060028018815170 · Cited by 12
Early life microbial exposure shapes subsequent animal health
Marcolla, C. S., Alvarado, C. S., & Willing, B. P. (2019) · Canadian Journal of Animal Science · doi:10.1139/cjas-2019-0029 · Cited by 11
“…usually considered more stable and resilient (Bäckhed et al. 2005), and decreased microbial taxonomic diversity has been frequently associated with inflammatory (Ott et al. 2004; Belkaid and Hand 2014) and infectious diseases (Chang et al. 2008; Caballero and Pamer 2015) in humans and mouse models.”
BackgroundZhong, J. W., Guo, K., Liao, Z.-L., Hu, S.-C., Du, Y., & Ji, X. (2022) · Coral Reefs · doi:10.1007/s00338-021-02200-z · Cited by 13
Treatment of Clostridium difficile infection in pediatric patients
Esposito, S., Umbrello, G., Castellazzi, L., & Principi, N. (2015) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/17474124.2015.1039988 · Cited by 11
“in patients with recurrent CDI episodes [3].”
Imhoff, A., & Karpa, K. D. (2009) · Nutrition in Clinical Practice · doi:10.1177/0884533608329232 · Cited by 14
Clostridium difficile Exposures, Colonization, and the Microbiome: Implications for Prevention
Revolinski, S., & Munoz-Price, L. S. (2018) · Infection Control and Hospital Epidemiology · doi:10.1017/ice.2018.36 · Cited by 13
Carr, A. V., Baliga, N. S., Diener, C., & Gibbons, S. M. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.04.28.538771 · Cited by 11
“2B; OLS R 2 =0.05, p =0.01), which is in line with prior empirical observations indicating that lower diversity communities are more susceptible to C. difficile colonization and the development of rCDI 9,27,32,33 .”
InfluentialAmakye, D., Ssentongo, P., Patel, S., Dalessio, S., Kochhar, S., Momin, A., & Clarke, K. (2025) · Crohn s & Colitis 360 · doi:10.1093/crocol/otaf024 · Cited by 16
“38, 39 Patients with IBD are at an increased risk of CDI due to several factors.”
Mikamo, H., Kondo, T., Okuyama, K., Marcella, S. W., & Ruzicka, D. J. (2019) · Anaerobe · doi:10.1016/j.anaerobe.2019.102139 · Cited by 11
Microbiome diversity predicts surgical success in patients with rectovaginal fistula
Leach, D. A., Chen, J., Yang, L., Chua, H. K., Walther-Antonio, M. R. S., & Occhino, J. A. (2020) · International Urogynecology Journal · doi:10.1007/s00192-020-04580-2 · Cited by 12
Global trends in gut microbiota and clostridioides difficile infection research: A visualized study
Li, Z., Ke, H., Lin, Q., Shen, Z., & Chen, Y. (2022) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2022.06.011 · Cited by 11
Clostridium difficileInfection: What's New?
Seo, G. S. (2013) · Intestinal Research · doi:10.5217/ir.2013.11.1.1 · Cited by 11
“따라 서 CDI 초 감염 때 FMT를 시도하는 것은 효과적이지 않을 수 있다.(64)”
Molecular Strain Typing and Characterisation of Toxigenic Clostridium difficile
Dingle, T. C., & MacCannell, D. (2015) · Methods in microbiology · doi:10.1016/bs.mim.2015.07.001 · Cited by 10
Urine-based metabolomic analysis of patients with Clostridium difficile infection: a pilot study
Kao, D. H., Ismond, K. P., Tso, V., Millan, B., Hotte, N., & Fedorak, R. N. (2016) · Metabolomics · doi:10.1007/s11306-016-1080-z · Cited by 10
“However, separations between (1) healthy control and CDI patients, as well as (2) patients with different episodes of CDI were possible and the permutations found were significant.”
BackgroundPerspectivas históricas y vigentes sobre la infección por Clostridium difficile
Álvarez-Hernández, D.-A., González-Chávez, A., Hermosillo-Cornejo, D. G., Kelly, G. A. F., Díaz-Girón-Gidi, A., & Vázquez-López, R. (2017) · Revista de Gastroenterología de México · doi:10.1016/j.rgmx.2017.03.004 · Cited by 14
Probiotics in the Rescue of Gut Inflammation
Ghosh, A. R. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-814625-5.00006-6 · Cited by 10
Dennie, J. G., Vandell, A. G., Inoue, S., Gajee, R., Pav, J. W., Zhang, G., Zamora, C. A., Masuda, N., Uchiyama, M., Yamada, M., et al. (2018) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1151 · Cited by 10
NIKOLAEVA, I. V., Shestakova, I. V., & Муртазина, Г. Х. (1993) · Бюллетень Восточно-Сибирского научного центра Сибирского отделения Российской академии медицинских наук · doi:10.29413/abs.2018-3.1.5 · Cited by 10
Impact of intrapartum antibiotics on the infant gastrointestinal microbiome: a narrative review
Diamond, L., Wine, R., & Morris, S. K. (2021) · Archives of Disease in Childhood · doi:10.1136/archdischild-2021-322590 · Cited by 11
Li, M., Li, Z., Shu, W., Liu, Y., Wang, Y., & Tang, L. (2016) · Future Microbiology · doi:10.2217/fmb-2015-0002 · Cited by 13
Kraft, C. S., Sims, M., Silverman, M., Louie, T. J., Feuerstadt, P., Huang, E. S., Khanna, S., Berenson, C. S., Wang, E. E. L., Cohen, S. H., et al. (2024) · Infectious Diseases and Therapy · doi:10.1007/s40121-024-01007-z · Cited by 12
Host origin of microbiota drives functional recovery and Clostridioides difficile clearance in mice
Millard, S., Vendrov, K. C., Young, V. B., & Seekatz, A. M. (2025) · mBio · doi:10.1128/mbio.01108-25 · Cited by 11
Self-citationExploring the etiology of colitis: insights from gut microbiota research
Qian, G., Chen, X., Liu, G., Yu, J., Zhong, S.-J., Yang, J., Sun, Y., & Zhou, J. (2025) · Gut Microbes · doi:10.1080/19490976.2025.2512010 · Cited by 15
“351 Specifically, there is a decrease in the abundance of butyrate-producing Faecalibacterium , Bifidobacterium , as well as Ruminococcaceae and Lachnospiraceae within the Firmicutes , leading to reduced synthesis of SCFAs and subsequent impairment of intestinal epithelial energy metabolism and…”
Nguyen, T. Q., Dao, T. K., Nguyen, H. D., Phung, T. B. T., Pham, T. T. N., Nguyen, T. V. H., Trinh, T. H., Le, H. C., Le, T. T. H., & Huyen, T. (2024) · Infectious Disease Reports · doi:10.3390/idr16050075 · Cited by 11
“As supported by previous studies, gastrointestinal infections such as Clostridium difficile [30] and rotavirus [31] also led to a reduction in the bacterial load and diversity.”
ResultNovel therapeutic strategies for Clostridium difficile infections
Ünal, C., & Steinert, M. (2015) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2016.1090428 · Cited by 13
“Especially, a decrease of members of Bacteriodes and Firmicutes after antibiotic treatment positively correlates with CDI [36].”
BackgroundRaz, N. E., & Bishara, J. (2018) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2018.1472184 · Cited by 12
“Thus intensive research is taking place, seeking microbiota-sparing antibiotics that, at least in part, overcome this limitation.(7)”
BackgroundJouhten, H., Ronkainen, A., Aakko, J., Salminen, S., Mattila, E. J., Arkkila, P., & Satokari, R. M. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.01663 · Cited by 10
“composition when compared to healthy individuals (Chang et al., 2008; Seekatz and Young, 2014).”
The Impact of Recurrent Clostridium difficile Infection on Patients’ Prevention Behaviors
Weaver, F. M., Trick, W. E., Evans, C. T., Lin, M., Adams, W., Pho, M. T., Bleasdale, S. C., Mullane, K. M., Johnson, S., Sikka, M. K., et al. (2017) · Infection Control and Hospital Epidemiology · doi:10.1017/ice.2017.208 · Cited by 12
“$25,000–$49,999 17 (22) 7 (19) 10 (26) $50,000–$99,999 18 (24) 9 (24) 9 (23) >$100,000 17 (22) 5 (13) 12 (31) Insurance (n= 108)”
Dietary therapy for clostridium difficile colonization: A case series
Suskind, D. L., Lee, D. Y., Solan, P., Wahbeh, G. T., Hayden, H. S., Brittnacher, M. J., Nuding, M. E., & Miller, S. I. (2019) · Anaerobe · doi:10.1016/j.anaerobe.2019.02.016 · Cited by 11
Clinical management of severe, fulminant, and refractoryClostridioides difficileinfection
Cheng, Y., & Fischer, M. (2020) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2020.1730814 · Cited by 11
Arcay, R. M., Barceló‐Nicolau, M., Suárez-Bode, L., Martín, L., Reigada, R., Höring, M., Liebisch, G., Garrido, C., Cabot, G., Vílchez, H., et al. (2024) · mBio · doi:10.1128/mbio.01347-24 · Cited by 14
Jess, A. T., Eskander, G. H., Vu, M. H., & Michail, S. K. (2023) · Metabolites · doi:10.3390/metabo13101039 · Cited by 10
Microbial community interactions on a chip
Juang, D. S., Wightman, W. E., Lozano, G. L., Juang, T. D., Barkal, L. J., Yu, J., Garavito, M. F., Hurley, A. I., Venturelli, O. S., Handelsman, J., et al. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2403510121 · Cited by 9
Metadata
- Authors
- Chang, J. Y., Antonopoulos, D. A., Kalra, A., Tonelli, A., Khalife, W. T., Schmidt, T. M., & Young, V. B.
- Affiliations
- Michigan State University (US)
- Corresponding author
- Young, Vincent B.
- Venue
- The Journal of Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2008-02
- Volume
- 197
- Issue
- 3
- Pages
- 435-438
- ISSN
- 0022-1899 (ISSN-L)
- 1537-6613
- OpenAlex
- W2139607253
- Cited by
- 1,010
- References
- 15
- Citations by year
- 2026: 15 · 2025: 28 · 2024: 36 · 2023: 54 · 2022: 42 · 2021: 57 · 2020: 69 · 2019: 59 · 2018: 107 · 2017: 78 · 2016: 77 · 2015: 88 · 2014: 87 · 2013: 78 · 2012: 53
- FWCI
- 17.27
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Infectious Diseases (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Clostridium difficile and Clostridium perfringens research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Microbiology (medical) › Bacterial Identification and Susceptibility Testing
- Keywords
- Clostridium difficile, fecal microbiota, microbial diversity, antibiotic-associated diarrhea, 16S rRNA gene sequencing, bacterial community composition, dysbiosis, microbiota restoration
- MeSH terms
- Anti-Bacterial Agents, Diarrhea, Drug Administration Schedule, Enterocolitis, Pseudomembranous, Feces, Female, Humans, Male, Phylogeny, Recurrence, Reference Values, Genetic Variation, Clostridioides difficile
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.